Fluticasone/formoterol combination inhaler launched
Clinical The Flutiform inhaler is indicated for the regular treatment of asthma where a corticosteroid/long-acting beta agonist is required and "also provides potential cost savings to the NHS".
A fluticasone/formoterol combination inhaler is now available on prescription, indicated for the regular treatment of asthma where a corticosteroid/long-acting beta agonist is required.
|
The inhaler does not require refrigeration and has a shelf life of two years |
 More on asthma
|
|
The Flutiform inhaler is available in three strengths: 50/5mcg, 125/5mcg for patients aged 12 years and older, and 250/10mcg, for patients aged 18 years and older. The inhaler does not require refrigeration and has a shelf life of two years. |
MUR project shows boost to respiratory outcomesThe treatment was "an alternative option for appropriate asthma patients in a device that patients are already familiar with", said Anna Murphy, consultant respiratory pharmacist at University Hospitals of Leicester NHS Trust.
"It also provides potential cost savings to the NHS – something that pharmacists and other healthcare colleagues are working hard to achieve."
|
How will this inhaler benefit your asthma patients? Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook |
